Strategic Asset Protection

De-Risk Every Deal with Biopharma Acquisition Cold Chain Due Diligence

Quantify risk and validate product integrity during M&A. TrueCold provides the granular data necessary to verify compliance history and ensure seamless integration.

  • Comprehensive historical temperature data audits.
  • Validation of existing infrastructure and sensor networks.
  • Gap analysis for GxP and regulatory alignment.

Schedule Compliance Review

Book a technical walkthrough with our biopharma compliance team to secure your assets.

What is Biopharma Acquisition Cold Chain Due Diligence?

In the high-stakes world of biopharma M&A, the value of a target often rests on the integrity of its temperature-sensitive inventory. Biopharma acquisition cold chain due diligence is the rigorous process of auditing a target company's storage and transport history to ensure every vial and pallet has remained within validated parameters. TrueCold accelerates this process with automated data reconciliation and real-time visibility tools.

Asset Integrity

Verify that clinical trial samples and commercial products haven't suffered silent excursions during the pre-deal phase.

Audit Readiness

Ensure that all temperature records are ALCOA+ compliant and ready for post-acquisition regulatory inspections.

Infrastructure Health

Evaluate the reliability and maintenance history of the target's refrigeration units and environmental monitoring systems.

Our Due Diligence Playbook

01

Data Harvesting

We aggregate historical temperature logs from disparate legacy systems into a single, unified TrueCold dashboard for analysis.

Technical Audit

Our team conducts a gap analysis of the current monitoring strategy, identifying potential vulnerabilities in the sensor network.

Risk Reporting

Receive a comprehensive report detailing the physical and digital risks to the cold chain, supporting accurate asset valuation.

Quantify Risk Before the Ink Dries

Don't inherit a liability. Our platform allows you to see exactly how your prospective acquisition manages its cold chain in real-time. By deploying TrueCold sensors during the due diligence period, you gain an unbiased, third-party window into operational discipline.

Industrial temperature monitoring system for biopharma acquisition cold chain due diligence

Why Leading PE Firms Trust TrueCold

Rapid Deployment

Deploy our hardware-agnostic software or wireless sensors in days, not weeks, to meet aggressive deal timelines.

Unified Compliance

Standardize monitoring across newly acquired global facilities with a single, validated cloud platform.

Actionable Insights

Move beyond raw data to predictive analytics that identify future equipment failures before they happen.

Frequently Asked Questions

How long does a cold chain due diligence audit take?
Typically, a preliminary data audit can be completed within 72 hours of receiving legacy logs. A full site-level technical assessment usually takes 5-7 business days depending on the geographical distribution of the assets.
Can you integrate with existing monitoring hardware?
Yes, TrueCold is hardware-agnostic. We can ingest data from most major logger brands and legacy BMS systems, providing a single source of truth without requiring immediate hardware replacement.
What specific regulations are covered in the audit?
Our audits are mapped to FDA 21 CFR Part 11, EU Annex 11, and WHO GXP guidelines. We ensure that all data captured during the due diligence process meets the highest global standards for biopharma integrity.

Ready to Secure Your Next Biopharma Deal?

Don't leave product integrity to chance. Partner with TrueCold for expert biopharma acquisition cold chain due diligence and enter your next merger with confidence.